Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.79 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.72 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.72 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.72 |
| ▸ | PRCP | P42785 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9511929 | 0.98 | NAAA (0.83) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL1678750 | 0.98 | NAAA (0.83) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL1679331 | 0.94 | NAAA (0.70) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL10174298 | 0.93 | NAAA (0.70) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL1753872 | 0.92 | NAAA (0.93) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL21880502 | 0.92 | NAAA (0.86) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL9603341 | 0.91 | NAAA (0.68) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL15189057 | 0.90 | NAAA (0.96) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL4555028 | 0.90 | NAAA (0.96) | NAAAGNAI3GNAO1GNAI1PRCP | |
| SCHEMBL31252296 | 0.90 | NAAA (0.90) | NAAAGNAI3GNAO1GNAI1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000012-B2 | Fungicide hydroximoyl-heterocycles derivatives | BAYER CROPSCIENCE AG (DE) | 2015-04-07 | — | — | US | claimed |
| US-20130040993-A1 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2013-02-14 | — | — | US | claimed |
| EP-2519502-A2 | FUNGICIDAL HYDROXIMOYL-HETEROCYCLES DERIVATIVES | Bayer CropScience AG (DE) | 2012-11-07 | — | — | EP | claimed |
| WO-2011080254-A2 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | WO | claimed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-9000012-B2 | Fungicide hydroximoyl-heterocycles derivatives | BAYER CROPSCIENCE AG (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130040993-A1 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-1632479-A2 | Piperazine derivatives useful as ccr5 antagonists | SCHERING CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1175401-B1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2004-04-08 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | NAAA 765/4885GNAI3 2573/4885GNAO1 3054/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | NAAA 4101/4885GNAI3 832/4885GNAO1 1414/4885 |
| US-20130040993-A1 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | HAAO, HPD, CYP51A1 | NAAA 387/4885GNAI3 3348/4885GNAO1 2865/4885 |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | NAAA 765/4885GNAI3 2573/4885GNAO1 3054/4885 |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | NAAA 4101/4885GNAI3 832/4885GNAO1 1414/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | NAAA 765/4885GNAI3 2573/4885GNAO1 3054/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | NAAA 765/4885GNAI3 2573/4885GNAO1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.